Global NGS Oncology Market Report 2022-2032: Increasing Incidence of Cancer Requiring Sophisticated Molecular Techniques Driving Growth

Company Logo

Global NGS Oncology Market

Global NGS Oncology Market

Dublin, July 13, 2022 (GLOBE NEWSWIRE) -- The "NGS Oncology Market - A Global and Regional Analysis: Focus on Offering, Sequencing Technology, Workflow, Application, End User, and Region - Analysis and Forecast, 2022-2032" report has been added to ResearchAndMarkets.com's offering.

Global NGS Oncology Market Industry Overview

The global NGS oncology market is projected to reach $51,783.0 million in 2032 from 14,828.6 million in 2021, witnessing a CAGR of 12.04% during the forecast period 2022-2032. The growth in the NGS oncology market is expected to be driven by an increasing number of panels or kits, bioinformatics services for computational analysis, and a rising number of open-source free sequencing platform providers offering NGS oncology.

Market Segmentation
by Sequencing Technology

• Targeted Sequencing

• Genomics

• Transcriptomics

• Epigenomics

by Offering

• Platform

• Kits

• Services

by Workflow

• Pre-Sequencing

• Sequencing

• Data Analysis

by Application

• Genetic Screening

• Hereditary Genetic Testing

• Hematological Malignancies

• Solid Tumors

• Other Applications

by End User

• Hospitals and Clinics

• Clinical Research Organizations (CROs)

• Academic and Research Institutes

• Pharmaceutical and Biotechnology Companies

• Other End Users

Demand - Drivers and Limitations
Following are the demand drivers for the global NGS Oncology Market:

• Increasing Incidence of Cancer Requiring Sophisticated Molecular Techniques

• Reducing Cost of Sequencing

• Rapid Technological Advancements Related to NGS Oncology

The market is expected to face some limitations too due to the following challenges:

• Inadequate NGS Oncology Reimbursement Scenario

• Increasing Cost of NGS Automated Sample Preparation Instruments

• Barriers in the Advancement of NGS Oncology

Key Market Players and Competition Synopsis

• Agilent Technologies, Inc.

• Bio-Rad Laboratories, Inc.

• Biodesix, Inc.

• Caris Life Sciences

• DNASTAR

• Fulgent Genetics, Inc.

• F. Hoffmann-La Roche Ltd

• Illumina, Inc.

• Invitae Corporation

• IntegraGen (OncoDNA)

• Oxford Nanopore Technologies plc.

• Pacific Biosciences of California, Inc.

• PerkinElmer, Inc.

• Pillar Biosciences, Inc.

• QIAGEN N.V.

• Thermo Fisher Scientific Inc.

• Takara Bio Inc.

• Vela Diagnostics

For more information about this report visit https://www.researchandmarkets.com/r/nd4kcu

Attachment

• Global NGS Oncology Market

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900